Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…MaaT PharmaMarch 31, 2025
Press Releases March 27, 2025: MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024…MaaT PharmaMarch 27, 2025
Press Releases March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…MaaT PharmaMarch 18, 2025
Press Releases January 8, 2025: MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013…MaaT PharmaJanuary 8, 2025
Press Releases January 7, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…MaaT PharmaJanuary 7, 2025
Press Releases December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH…MaaT PharmaDecember 10, 2024
Press Releases December 5, 2024: MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded…MaaT PharmaDecember 5, 2024
Press Releases October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…MaaT PharmaOctober 15, 2024
Press Releases April 22, 2024: MaaT Pharma to Hold Annual General Meeting on May 28, 2024 MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd…MaaT PharmaApril 22, 2024